GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (MIL:1GILD) » Definitions » Construction In Progress

Gilead Sciences (MIL:1GILD) Construction In Progress : €606 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Gilead Sciences Construction In Progress?

Gilead Sciences's quarterly construction in progress stayed the same from Jun. 2023 (€0 Mil) to Sep. 2023 (€0 Mil) but then increased from Sep. 2023 (€0 Mil) to Dec. 2023 (€606 Mil).

Gilead Sciences's annual construction in progress declined from Dec. 2021 (€935 Mil) to Dec. 2022 (€679 Mil) and declined from Dec. 2022 (€679 Mil) to Dec. 2023 (€606 Mil).


Gilead Sciences Construction In Progress Historical Data

The historical data trend for Gilead Sciences's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Construction In Progress Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 650.70 703.63 935.45 678.74 606.14

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 678.74 - - - 606.14

Gilead Sciences Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Gilead Sciences (MIL:1GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (MIL:1GILD) Headlines

No Headlines